At a glance
ClinicalIndex Comparison RecordN/ACompleted· 27 enrolled
Drug / intervention
Alpharadindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Observation, Open Label Study of Alpharadin (Radium 223) in Patients With Castrate Resistant Prostate Cancer Bone Metastases
In Brief
A clinical study evaluating Alpharadin for Prostate Cancer. Completed, enrolled 27 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn more about how the study drug alpharadin (Radium-223) works in patients who have CPRC that has spread to the bone.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
CollaboratorsBayer, Prostate Cancer Foundation
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMay 2014
Enrollment StartSep 2014
Primary CompletionNov 2020
TodayJul 2026
First PostedMay 12, 2014
Enrollment StartSep 19, 2014
Primary CompletionNov 11, 2020
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 12.1 years ago
Interventions
Alpharadindrug
50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).